Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286580 · ClinicalTrials.gov registry record · NA
Standardization of Non-academic Center Surgical Morbidity and Mortality Conference: a Type I Hybrid Implementation Non-clinical Trial.
A NA study, sponsored by Poudre Valley Health System.
- Terminated
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT05286580: Clinical Trial NA study, sponsored by Poudre Valley Health System.
NCT05286580 is a NA study that was terminated before completion, run by Poudre Valley Health System. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05286580, a NA study, was terminated before completion, sponsored by Poudre Valley Health System.
- TERMINATED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
* Specific Aim 1: Determine impact of standardized morbidity and mortality (M\&M) toolkit on provider satisfaction with, and perceived impact of, M\&M conference. * Specific Aim 2: Identify barriers and facilitators to toolkit implementation.
Primary Outcome
Participant endorses having seen a change at their institution attributable to a discussion at an M\&M conference
Interventions
- BEHAVIORAL Morbidity and mortality conference toolkit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2023-02-06 |
| Phase | NA |
Why NCT05286580 stopped before completion
NCT05286580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Morbidity and mortality conference toolkit is the first listed.
NCT05286580 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05286580 about?
NCT05286580 is a clinical study titled "Standardization of Non-academic Center Surgical Morbidity and Mortality Conference: a Type I Hybrid Implementation Non-clinical Trial.". * Specific Aim 1: Determine impact of standardized morbidity and mortality (M\&M) toolkit on provider satisfaction with, and perceived impact of, M\&M conference. * Specific Aim 2: Identify barriers and facilitators to toolkit implementation.
What is the current status of trial NCT05286580?
This trial is currently terminated. It is a NA study. The enrollment target is 28 participants. The study started on 2022-03-24. Estimated completion is 2023-02-06.
What interventions are being tested in trial NCT05286580?
The interventions under investigation include: Morbidity and mortality conference toolkit (BEHAVIORAL).
Who is sponsoring clinical trial NCT05286580?
This trial is sponsored by Poudre Valley Health System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05286580's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI